Metallothionein Expression Is Suppressed in Primary Human Hepatocellular Carcinomas and Is Mediated through Inactivation of CCAAT/Enhancer Binding Protein α by Phosphatidylinositol 3-Kinase Signaling Cascade
Open Access
- 15 March 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (6), 2736-2746
- https://doi.org/10.1158/0008-5472.can-06-4433
Abstract
Reactive oxygen species (ROS) resulting from chronic inflammation cause liver injury leading to transformation of regenerating hepatocytes. Metallothioneins (MT), induced at high levels by oxidative stress, are potent scavengers of ROS. Here, we report that the levels of MT-1 and MT-2A are drastically reduced in primary human hepatocellular carcinomas (HCCs) and in diethylnitrosamine-induced liver tumors in mice, which is primarily due to transcriptional repression. Expression of the transcription factor, MTF-1, essential for MT expression, and its target gene Zn-T1 that encodes the zinc transporter-1 was not significantly altered in HCCs. Inhibitors of both phosphatidylinositol 3-kinase (PI3K) and its downstream target AKT increased expression of MT genes in HCC cells but not in liver epithelial cells. Suppression of MT-1 and MT-2A by ectopic expression of the constitutively active PI3K or AKT and their up-regulation by dominant-negative PI3K or AKT mutant confirmed negative regulation of MT expression by PI3K/AKT signaling pathway. Further, treatment of cells with a specific inhibitor of glycogen synthase kinase-3 (GSK-3), a downstream effector of PI3K/AKT, inhibited MT expression specifically in HCC cells. Short interfering RNA–mediated depletion of CCAAT/enhancer binding protein α (C/EBPα), a target of GSK-3, impeded MT expression, which could not be reversed by PI3K inhibitors. DNA binding activity of C/EBPα and its phosphorylation at T222 and T226 by GSK-3 are required for MT expression. MTF-1 and C/EBPα act in concert to increase MT-2A expression, which probably explains the high level of MT expression in the liver. This study shows the role of PI3K/AKT signaling pathway and C/EBPα in regulation of MT expression in hepatocarcinogenesis. [Cancer Res 2007;67(6):2736–46]Keywords
All Related Versions
This publication has 52 references indexed in Scilit:
- Viral hepatitis and liver cancer: the case of hepatitis COncogene, 2006
- Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicityOncogene, 2006
- Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesisOncogene, 2006
- Cyclin D3 Maintains Growth-Inhibitory Activity of C/EBPα by Stabilizing C/EBPα-cdk2 and C/EBPα-Brm ComplexesMolecular and Cellular Biology, 2006
- RETRACTED: Physical and Functional Interaction of DNA Methyltransferase 3A with Mbd3 and Brg1 in Mouse Lymphosarcoma CellsCancer Research, 2005
- Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agentsThe Esophagus, 2004
- Metallothionein deficiency enhances skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate in metallothionein-null miceCarcinogenesis: Integrative Cancer Research, 2003
- Treatment of hepatocellular carcinoma: is there an optimal strategy?Cancer Treatment Reviews, 2003
- Silencing of metallothionein-I gene in mouse lymphosarcoma cells by methylationOncogene, 1999
- Metallothionein Overexpression Supresses Hepatic Hyperplasia Induced by Hepatitis B Surface AntigenToxicology and Applied Pharmacology, 1999